Advertisement AstraZeneca and Starpharma sign drug delivery technology deal - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

AstraZeneca and Starpharma sign drug delivery technology deal

AstraZeneca has signed a licensing agreement to use Starpharma's DEP drug delivery technology in the development and commercialization of an oncology compound on signature.

Vaccine vails

AstraZeneca agreed to pay a signature amount of $2m on execution of the deal. It has potential for follow on compounds directed at a defined family of targets.

The deal will also see Starpharma receive development and launch related milestone payments of about $64m and sales milestones totaling up to $60m based on specific annual sales for the first product developed by AstraZeneca.

Each subsequent product that qualifies under the collaboration is expected to attract development and regulatory milestone payments of up to $53.3m, while potential sales milestone payments on specific annual sales could total $40m.

Australia-based Starpharma is also eligible to receive tiered royalties on net sales of the products.

AstraZeneca will fund all development and commercialization costs including ongoing and future collaborative work carried out with Starpharma.

Starpharma CEO Jackie Fairley said: "Today’s agreement with AstraZeneca is an exciting development for Starpharma and its DEP platform.

"It follows a successful collaboration in which Starpharma’s DEP drug delivery technology has been applied to an important AstraZeneca oncology candidate."

Starpharma estimates that each qualifying product commercialized under the deal could be worth over its life around $450m to it. The company says the value may be more based on the range of indications and degree of commercial success in the market.

AstraZeneca oncology innovative medicines unit head Susan Galbraith said: "This license agreement will enable us to further harness the DEP technology and evaluate its potential across novel molecules within our oncology portfolio.”


Image: AstraZeneca will use Starpharma’s DEP drug delivery technology to develop and commercialize an oncology compound on signature. Photo: courtesy of Starpharma Holdings Limited.